Advisory Services Network’s Summit Therapeutics SMMT Stock Holding History

Advisory Services Network’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-600	Closed	-$4K	–	2962
2021 Q2	$4K	Buy	+600	New	+$3.94K	﹤0.01%	3168
2021 Q1	–	Sell	-600	Closed	-$3K	–	2705
2020 Q4	$3K	Sell	600 -7,000	-92%	-$29.6K	﹤0.01%	2921
2020 Q3	$26K	Buy	+7,600	New	+$26.3K	﹤0.01%	1950
2020 Q2	–	Sell	-7,000	Closed	-$17K	–	2485
2020 Q1	$17K	Hold	7,000	–	–	﹤0.01%	1964
2019 Q4	$11K	Buy	+7,000	New	+$11.3K	﹤0.01%	2322

Other funds holding SMMT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Advisory Services Network's SMMT Position: Q3 2021 in Review

Advisory Services Network sold out of Summit Therapeutics (SMMT) in Q3 2021, closing a stake of 600 shares — an estimated $4K sold.

Advisory Services Network first reported a position in SMMT in Q4 2019 and held it in 5 quarters. The position peaked at $26K in Q3 2020. 54 funds tracked by Wall St. Rank hold SMMT as of Q3 2021.

Advisory Services Network reported no remaining Summit Therapeutics position as of Q3 2021 after selling out during the quarter.
Advisory Services Network sold 600 Summit Therapeutics shares in Q3 2021, an estimated $4K.
Advisory Services Network first reported a position in Summit Therapeutics in Q4 2019 and held it in 5 quarters.
Advisory Services Network's Summit Therapeutics position peaked at $26K in Q3 2020.
54 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2021.

Based on Advisory Services Network's 13F filing for Q3 2021, filed 5 Nov 2021.